CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
- 22 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 124 (1), 23-35
- https://doi.org/10.1007/s00401-012-0983-7
Abstract
The effects of applying clinical versus neuropathological diagnosis and the inclusion of cases with coincident neuropathological diagnoses have not been assessed specifically when studying cerebrospinal fluid (CSF) biomarker classification cutoffs for patients with neurodegenerative diseases that cause dementia. Thus, 142 neuropathologically diagnosed neurodegenerative dementia patients [71 Alzheimer’s disease (AD), 29 frontotemporal lobar degeneration (FTLD), 3 amyotrophic lateral sclerosis, 7 dementia with Lewy bodies, 32 of which cases also had coincident diagnoses] were studied. 96 % had enzyme-linked immunosorbant assay (ELISA) CSF data and 77 % had Luminex CSF data, with 43 and 46 controls for comparison, respectively. Aβ42, total, and phosphorylated tau181 were measured. Clinical and neuropathological diagnoses showed an 81.4 % overall agreement. Both assays showed high sensitivity and specificity to classify AD subjects against FTLD subjects and controls, and moderate sensitivity and specificity for classifying FTLD subjects against controls. However, among the cases with neuropathological diagnoses of AD plus another pathology (26.8 % of the sample), 69.4 % (ELISA) and 96.4 % (Luminex) were classified as AD according to their biomarker profiles. Use of clinical diagnosis instead of neuropathological diagnosis led to a 14–17 % underestimation of the biomarker accuracy. These results show that while CSF Aβ and tau assays are useful for diagnosis of AD and neurodegenerative diseases even at MCI stages, CSF diagnostic analyte panels that establish a positive diagnosis of Lewy body disease and FTLD are also needed, and must be established based on neuropathological rather than clinical diagnoses.Keywords
This publication has 66 references indexed in Scilit:
- Evidence for Ordering of Alzheimer Disease BiomarkersArchives of Neurology, 2011
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionAnnals of Neurology, 2010
- Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental IllnessArchives of Neurology, 2010
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an updateActa Neuropathologica, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- The neuropathology of probable Alzheimer disease and mild cognitive impairmentAnnals of Neurology, 2009
- Clinical and Pathological Continuum of Multisystem TDP-43 ProteinopathiesArchives of Neurology, 2009
- Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathiesActa Neuropathologica, 2009
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991